|
|
| | JNJ-49095397 Basic information |
| Product Name: | JNJ-49095397 | | Synonyms: | JNJ-49095397;JNJ-49095397
(RV568;RV-568;Acetamide, N-[4-[[[4-[[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]-1-naphthalenyl]oxy]methyl]-2-pyridinyl]-2-methoxy- | | CAS: | 1220626-82-3 | | MF: | C34H36N6O4 | | MW: | 592.69 | | EINECS: | | | Product Categories: | | | Mol File: | 1220626-82-3.mol |  |
| | JNJ-49095397 Chemical Properties |
| Boiling point | 738.0±60.0 °C(Predicted) | | density | 1.23±0.1 g/cm3(Predicted) | | pka | 12.13±0.70(Predicted) | | form | Solid | | color | Off-white to gray |
| | JNJ-49095397 Usage And Synthesis |
| Uses | JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 also inhibits SRC kinase family, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma[1]. | | in vivo | JNJ-49095397 (RV568) (1-20 μg/mouse; intratracheal; once) shows anti-inflammatory activities in LPS-induced neutrophil accumulation mouse model[1]. | Animal Model: | Nonfasted Balb/c mice, LPS-induced neutrophil accumulation model[1] | | Dosage: | 1, 4 and 20 μg/mouse | | Administration: | Intratracheal administration, 2, 8 or 12 h prior to LPS inhalation | | Result: | Prevented the accumulation of neutrophils in the BAL fluid. Significantly inhibited neutrophil accumulation when administered up to 8 h prior to LPS inhalation. |
| | IC 50 | p38α; p38γ; Haematopoietic Kinase (HCK) | | References | [1] Charron CE, et al. RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation. Eur Respir J. 2017 Oct 26;50(4):1700188. DOI:10.1183/13993003.00188-2017 |
| | JNJ-49095397 Preparation Products And Raw materials |
|